| Literature DB >> 31336895 |
Clément Offret1,2, Ismaïl Fliss1,2, Laurent Bazinet1,2, André Marette1,3, Lucie Beaulieu4,5.
Abstract
The Atlantic mackerel, Scomber scombrus, is one of the most fished species in the world, but it is still largely used for low-value products, such as bait; mainly for crustacean fishery. This resource could be transformed into products of high value and may offer new opportunities for the discovery of bioactive molecules. Mackerel hydrolysate was investigated to discover antibacterial peptides with biotechnological potential. The proteolytic process generated a hydrolysate composed of 96% proteinaceous compounds with molecular weight lower than 7 kDa. From the whole hydrolysate, antibacterial activity was detected against both Gram-negative and Gram-positive bacteria. After solid phase extraction, purification of the active fraction led to the identification of 4 peptide sequences by mass spectrometry. The peptide sequence N-KVEIVAINDPFIDL-C, called Atlantic Mackerel GAPDH-related peptide (AMGAP), was selected for chemical synthesis to confirm the antibacterial activity and to evaluate its stability through in vitro digestibility. Minimal inhibitory concentrations of AMGAP revealed that Listeria strains were the most sensitive, suggesting potential as food-preservative to prevent bacterial growth. In addition, in vitro digestibility experiments found rapid (after 20 min) and early digestibility (stomach). This study highlights the biotechnological potential of mackerel hydrolysate due to the presence of the antibacterial AMGAP peptide.Entities:
Keywords: Atlantic mackerel; antimicrobial peptide; hydrolysate; in vitro digestibility
Year: 2019 PMID: 31336895 PMCID: PMC6669513 DOI: 10.3390/md17070413
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Total amino acids in the hydrolysate (g/100 g) from processing of Atlantic mackerel (10,000–200 Da retentate). Analyses were conducted in duplicate.
| Amino Acids | Mackerel Hydrolysate |
|---|---|
| Glutamic acid | 13.23 ± 0.70 |
| Aspartic acid | 8.31 ± 0.28 |
| Lysine | 7.14 ± 0.46 |
| Leucine | 5.37 ± 0.13 |
| Glycine | 5.06 ± 0.29 |
| Arginine | 4.71 ± 0.15 |
| Alanine | 4.97 ± 0.07 |
| Proline | 3.43 ± 0.19 |
| Valine | 3.39 ± 0.25 |
| Threonine | 3.40 ± 0.09 |
| Serine | 3.27 ± 0.20 |
| Histidine | 3.17 ± 0.26 |
| Phenylalanine | 2.30 ± 0.19 |
| Isoleucine | 2.51 ± 0.21 |
| Tyrosine | 2.04 ± 0.18 |
| Methionine | 1.88 ± 0.16 |
| Taurine | 0.48 ± 0.03 |
| Cysteine | 0.27 ± 0.03 |
| Tryptophan | 0.64 ± 0.02 |
|
| 75.57 |
Figure 1Molecular weight distribution obtained after injection of the mackerel hydrolysate (10,000–200 Da retentate) into the FPLC system.
Figure 2Growth kinetics of bacterial targets in presence of the SPE-C18 fraction at 0 (filled circles), 43 (diamonds), 86 (triangles) and 172 (square) µg/mL.
Purification of antibacterial peptides from hydrolysate of whole mackerel.
| Purification Step | Volume (mL) | Total Protein (mg) | Total Activity (AU) | Specific Activity (AU/mg) | Increase in Specific Activity (fold) | Activity Recovery (%) |
|---|---|---|---|---|---|---|
|
| 50 | 1.25 × 103 | 1.00 × 106 | 8.00 × 101 | / | 100 |
|
| 1.0 | 1.48 × 100 | 6.40 × 105 | 4.32 × 105 | 5405 | 64 |
|
| 0.5 | 1.70 × 10−2 | 2.00 × 104 | 1.18 × 106 | 14,706 | 2 |
|
| 0.3 | 4.00 × 10−3 | 6.00 × 103 | 1.67 × 106 | 20,833 | 1 |
Figure 3RP-HPLC chromatogram of antibacterial peptide fraction from the second RP-HPLC eluate. The absorbance was monitored at 214 nm and expressed as mAU (arbitrary units of absorbance).
Peptide fragments identified by MS/MS analysis, with more than 75% homology to antibacterial proteins from CAMP. Peptide sequence properties and their related precursor proteins were obtained from ExPASY and Scaffold (protein-threshold probability > 95%) analyses, respectively.
| Scaffold Analysis | ExPASy Analysis | CAMP Database | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peptide Sequences | Precursor Proteins | Charge | GRAVY Index | Stability | pI | Antibacterial-Peptide Related | Access Number | Homology | Organisms | |
| (1) | KVEIVAINDPFIDL | Glyceraldehyde-3-phosphate dehydrogenase | −2 | 0.771 | Stable | 4.03 | YFGAP | CAMPSQ3690 | 89% |
|
| (2) | LILLILLLLKLLLLLI | N-acetylmuramoyl-L-alanine amidase | +1 | 3.450 | Stable | 8.75 | Beta-defensin | CAMPSQ4887 | 75% |
|
| (3) | LLILLLLKLLLLLI | +1 | 3.350 | Stable | 8.75 | CAMPSQ4886 | 75% |
| ||
| (4) | LLILLLLLLILLLILLPF | Syndecan domain | 0 | 3.561 | Unstable | 5.52 | Beta-defensin | CAMPSQ4886 | 75% |
|
MIC of the synthetic peptide (AMGAP) expressed in mM. ND, non-determined.
|
|
| Strains | MIC (mM) |
|---|---|---|---|
|
|
| B301 | >1.050 |
|
|
| ATCC 29236 | >1.050 |
|
|
| ATCC 15697 | >1.050 |
|
|
| ATCC 29212 | >1.050 |
|
|
| L1 | >1.050 |
|
|
| ATCC 4356 | 0.263 |
|
|
| 16 | ND |
|
|
| ATCC 19119 | 0.131 |
|
|
| ATCC 15313 | 0.131 |
|
|
| 272 | 0.263 |
|
|
| ATCC 25923 | >1.050 |
|
|
| ATCC 29741 | 0.263 |
|
|
| ATCC 25922 | >1.050 |
|
|
| ATCC 27853 | >1.050 |
|
|
| ALN-0312 | >1.050 |
Figure 4FPLC profile of the synthetic peptide after digestion using dynamic GI TIM-1. Samples collected from the stomach before digestion (solid line) and after 20 min of digestion (short dash), and from the duodenum (long dash).
Bacterial targets used for screening of antibacterial activity from hydrolysate. BHI, Brain Heart Infusion; LB, Luria-Bertani; TSB, Tryptone Soy Broth; YE, Yeast Extract; YEG, Yeast Extract Glucose.
| Target strains | Growth Conditions | ||||
|---|---|---|---|---|---|
| Genus |
| Collection | Type | Ecological Function | Media |
|
|
| B301 | Gram † | Non-pathogen | TSB |
|
|
| ATCC 29236 | Human Flora | BHI + Cysteine (0.05%) | |
|
|
| ATCC 15697 | Human probiotic | BHI + Cysteine (0.05%) | |
|
|
| ATCC 27212 | Human pathogen | BHI | |
|
|
| L1 | Human pathogen | BHI | |
|
|
| ATCC 4356 | Human probiotic | TSB+YE (0.6%) | |
|
|
| 16 | Human probiotic | BHI + Cysteine (0.05%) | |
|
|
| ATCC 19119 | Human pathogen | TSB+YE (0.6%) | |
|
|
| ATCC 15313 | Human pathogen | MRS | |
|
|
| 272 | Non-pathogen | TSB | |
|
|
| ATCC 25923 | Human pathogen | BHI | |
|
|
| ATCC 29741 | Human pathogen | BHI + Cysteine (0.05%) | |
|
|
| ATCC 25922 | Human pathogen | LB | |
|
|
| ATCC 27853 | Human pathogen | TSB | |
|
|
| ALN-0312 | Human pathogen | BHI + Sea salt (3%) | |
† Laboratoire de Microbiologie Alimentaire (LMA) strain collection (Laval University, QC, Canada).